Neuronetics is trading at $2.49, up +10.37%, with no confirmed company-specific catalyst for the move.
- Third-quarter 2026 results were scheduled for release before market open, with a call at 8:30 a.m. ET.
- Healthcare was higher pre-market, offering broader sector support; this does not establish the cause of Neuronetics’ gain.